Weltjournal für Pharmakologie und Toxikologie

Abstrakt

Monitoring the Effects of Ligustilide on Mice with Idiopathic Pulmonary Fibrosis and Determining the Underlying Mechanism

Jin Wang

Idiopathic pulmonary fibrosis is a chronic interstitial lung condition that currently lacks viable treatment options. One of angelica’s key bioactive ingredients is ligustilide (LIG). The current study’s objectives were to investigate the underlying mechanism and monitor the impact of LIG on mice with advanced pulmonary fibrosis lung fibrosis. After a single BLM instillation of 14 days, the mice received daily LIG treatment for 2 weeks. Then the effect of LIG on lung fibrosis was observed then. The impact of LIG on pulmonary fibrosis was assessed using the pulmonary function test, Hematoxylin-Eosin (H&E) and Masson’s trichrome staining, immunofluorescence, and Western blot. Following in vitro therapy with transforming growth factor 1 (TGF-1), we looked into the underlying mechanism.